FDA Approves AstraZeneca's Camizestrant (Etcamah) for Breast Cancer

The FDA has approved AstraZeneca's camizestrant, marketed as Etcamah, for breast cancer. The approval expands treatment options for specific patient populations, though the exact indication is not detailed in the source. This is a regulatory milestone for AstraZeneca, potentially affecting its oncology portfolio and competitive positioning.